LYL-132

N/A

Report date: 2022/05/06 16:54:51

Base Information

Drug NameLYL-132
Drug Alias NameLYL-132GSK-4427296
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionCancer/testis antigen 1 modulators
TargetsCancer/testis antigen 1
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[6] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesLyell Immunopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcLyell Immunopharma Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A